Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Merck (Pty) Ltd
See ingredients
TABLET
EACH TABLET CONTAINS METFORMIN HYDROCHLORIDE 850 mg
Registered
1977-01-04
GLUCOPHAGE XR 500 MG, XR 750 MG AND XR 1000 MG PROFESSIONAL INFORMATION SCHEDULING STATUS: S3 1. NAME OF THE MEDICINE Glucophage XR 500 mg (prolonged release tablet) Glucophage XR 750 mg (prolonged release tablet) Glucophage XR 1000 mg (prolonged release tablet) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged release GLUCOPHAGE XR 500 MG tablet contains 500 mg metformin hydrochloride corresponding to 390 mg metformin base. Each prolonged release GLUCOPHAGE 750 XR MG tablet contains 750 mg metformin hydrochloride corresponding to 585 mg metformin base. Each prolonged release GLUCOPHAGE XR 1000 MG tablet contains 1 000 mg metformin hydrochloride corresponding to 780 mg metformin base. Sugar-free. For a full list of excipients, see Section 6.1. 3. PHARMACEUTICAL FORM Glucophage XR 500 mg: White to off-white, round, biconvex tablet of 12 mm diameter, debossed on one side with “500”. Glucophage XR 750 mg: White to off-white, capsule-shaped, biconvex tablet of 19 mm length, debossed on one side with “750” and on the other side with “Merck”. Glucophage XR 1000 mg: White to off-white, capsule-shaped, biconvex tablet of 22 mm length, debossed with “1000” on one face and “Merck” on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Risk reduction or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with prediabetes (IGT* and/or IFG*, and/or increased HbA1c) and additional risk factors**, in whom lifestyle change has not resulted in adequate glycaemic control. Lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons. *IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose ** Identified risk factors include obesity, age, hypertension, cardiovascular disease, family history of diabetes, dyslipidaemia, gestational diabetes, and Polycystic ovary syndrome (PCOS). • Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary Read the complete document
GLUCOPHAGE 500 MG, 850 MG AND 1 000 MG PI SCHEDULING STATUS: S3 1. NAME OF THE MEDICINE GLUCOPHAGE 500 MG TABLET GLUCOPHAGE 850 MG TABLET GLUCOPHAGE 1 000 MG TABLET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each GLUCOPHAGE 500 MG tablet contains 500 mg metformin hydrochloride corresponding to 390 mg metformin base. Each GLUCOPHAGE 850 MG tablet contains 850 mg metformin hydrochloride corresponding to 663 mg metformin base. Each GLUCOPHAGE 1 000 MG tablet contains 1 000 mg metformin hydrochloride corresponding to 780 mg metformin base. Sugar-free. For a full list of excipients, see Section 6.1. 3. PHARMACEUTICAL FORM GLUCOPHAGE 500 mg: White, round, biconvex, film-coated tablets. GLUCOPHAGE 850 mg: White, round, convex, film-coated tablets. GLUCOPHAGE 1 000 mg: White, oval, biconvex, bisected, film-coated tablets with “1000” embossed on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of type 2 diabetes mellitus, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. • In adults, Glucophage film-coated tablets may be used as monotherapy or in combination with other oral antidiabetic medicines or with insulin. • In children over 12 years of age and adolescents with type 2 diabetes mellitus, Glucophage film-coated tablets may be used as monotherapy or in combination with insulin. A reduction of diabetic complications has been shown in overweight type 2 diabetic adult patients treated with metformin hydrochloride immediate-release as first-line therapy after diet failure. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION It is important that Glucophage tablets be taken in divided doses with meals. MONOTHERAPY OR COMBINATION WITH OTHER ORAL ANTIDIABETIC MEDICINES ADULTS • Initially, one 500 mg tablet three times a day, or one 850 mg or 1 000 mg tablet twice a day, with or after meals. • After 10 to 15 days the dose should be adjusted according to blood glucose measurements. A slow increase in dose may improve gastroint Read the complete document